Last 12 months
Inside the activity.
2 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 1 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2020 Filed Mar 13, 2020 12:41 UTC |
Elston GeorgeChief Financial Officer
|
PurchaseCommon Stock | 10,000 | $0.96 | $9,600.00 |
DisclosureSEC source: 0001562180-20-002451 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 12:40 UTC |
Lurker NancyDirector · President & CEO
|
PurchaseCommon Stock | 98,000 | $1.06 | $104,027.00 |
DisclosureSEC source: 0001562180-20-002379 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 38,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002044 · primarydocument.xml · derivative · entry 2 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC |
ANDO GORANDirector
|
GrantRestricted Stock Units · Derivative | 21,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002044 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:01 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 246,250 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002043 · primarydocument.xml · derivative · entry 2 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,250 Underlying: Common Stock · 246,250 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begin March 28, 2020 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:01 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 123,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002043 · primarydocument.xml · derivative · entry 1 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,150 Underlying: Common Stock · 123,150 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:07 UTC |
Peterson KristineDirector
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002050 · primarydocument.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:07 UTC |
Peterson KristineDirector
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002050 · primarydocument.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002045 · primarydocument.xml · derivative · entry 2 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:02 UTC |
Landis John B.Director
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002045 · primarydocument.xml · derivative · entry 1 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:56 UTC |
Lurker NancyDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 748,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002036 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 748,000 Underlying: Common Stock · 748,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begin March 28, 2020 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:56 UTC |
Lurker NancyDirector · President & CEO
|
GrantRestricted Stock Units · Derivative | 374,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002036 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,000 Underlying: Common Stock · 374,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:06 UTC |
Elston GeorgeChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 110,371 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002048 · primarydocument.xml · derivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,371 Underlying: Common Stock · 110,371 shares Expires 2030-02-28 F1 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which begins March 28, 2020 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:06 UTC |
Godshall Douglas EvanDirector
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002049 · primarydocument.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:06 UTC |
Godshall Douglas EvanDirector
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002049 · primarydocument.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:03 UTC |
DICICCO WENDY FDirector
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002046 · primarydocument.xml · derivative · entry 2 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:03 UTC |
DICICCO WENDY FDirector
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002046 · primarydocument.xml · derivative · entry 1 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:25 UTC |
GUYER DAVID RDirector
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002051 · primarydocument.xml · derivative · entry 2 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:25 UTC |
GUYER DAVID RDirector
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002051 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:57 UTC |
Mazzo David JDirector
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002054 · primarydocument.xml · derivative · entry 2 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:57 UTC |
Mazzo David JDirector
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002054 · primarydocument.xml · derivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:04 UTC |
Duker Jay S.Director
|
GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002047 · primarydocument.xml · derivative · entry 2 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:04 UTC |
Duker Jay S.Director
|
GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002047 · primarydocument.xml · derivative · entry 1 Duker Jay S. · CIK 0001630864 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:01 UTC |
Paggiarino Dario A.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 246,250 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002042 · primarydocument.xml · derivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,250 Underlying: Common Stock · 246,250 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:01 UTC |
Paggiarino Dario A.Chief Medical Officer
|
GrantRestricted Stock Units · Derivative | 123,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002042 · primarydocument.xml · derivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,150 Underlying: Common Stock · 123,150 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. F1 · derivative.expiration_date: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:50 UTC |
Lurker NancyDirector · President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 137,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001682 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,349 Underlying: Common Stock · 137,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning February 21, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:50 UTC |
Lurker NancyDirector · President & CEO
|
Exercise / conversionCommon Stock | 137,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001682 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25,171 shares acquired on January 31, 2020 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 13:42 UTC |
Elston GeorgeChief Financial Officer
|
PurchaseCommon Stock | 10,000 | $1.43 | $14,290.00 |
DisclosureSEC source: 0001562180-19-005548 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 13:42 UTC |
Elston GeorgeChief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 745,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001562180-19-005548 · primarydocument.xml · derivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,000 Underlying: Common Stock · 745,000 shares Expires 2029-11-14 F1 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remainig thirty-six months Read SEC document |
| October 12, 2019 Filed Oct 15, 2019 22:04 UTC |
Lurker NancyDirector · President & CEO
|
Tax withholdingCommon Stock | 10,745 | $2.11 | $22,618.23 |
DisclosureSEC source: 0001562180-19-005160 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,455 F1 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units F2 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on October 11, 2019 Read SEC document |
| October 12, 2019 Filed Oct 15, 2019 22:03 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 2,450 | $2.11 | $5,157.25 |
DisclosureSEC source: 0001562180-19-005159 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,047 F1 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units F2 · price: Reflects the last reported sale price for the Registrant's shares of common stock on the Nasdaq Global Market on October 11, 2019 Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 22:13 UTC |
Mazzo David JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001562180-19-005150 · primarydocument.xml · derivative · entry 2 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2028-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 22:13 UTC |
Mazzo David JDirector
|
Exercise / conversionCommon Stock | 33,333 | $1.95 | $64,999.35 |
DisclosureSEC source: 0001562180-19-005150 · primarydocument.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 12:46 UTC |
Mazzo David JDirector
|
Exercise / conversionDeferred Stock Unit · Derivative | 417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004701 · primarydocument.xml · derivative · entry 2 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On September 6, 2018, the reporting person was granted 417 DSUs. The DSUs vested in full on September 6, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On September 6, 2018, the reporting person was granted 417 DSUs. The DSUs vested in full on September 6, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On September 6, 2018, the reporting person was granted 417 DSUs. The DSUs vested in full on September 6, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 12:46 UTC |
Mazzo David JDirector
|
Exercise / conversionCommon Stock | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004701 · primarydocument.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 16:39 UTC |
DICICCO WENDY FDirector
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001562180-19-003959 · primarydocument.xml · derivative · entry 1 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-07-15 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on July 15, 2020. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 17:04 UTC |
Ross Leonard SSee Remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003677 · primarydocument.xml · derivative · entry 3 Ross Leonard S · CIK 0001458753 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 17:04 UTC |
Ross Leonard SSee Remarks
|
Tax withholdingCommon Stock | 1,961 | $1.65 | $3,235.65 |
DisclosureSEC source: 0001562180-19-003677 · primarydocument.xml · nonDerivative · entry 2 Ross Leonard S · CIK 0001458753 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,044 F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 17:04 UTC |
Ross Leonard SSee Remarks
|
Exercise / conversionCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003677 · primarydocument.xml · nonDerivative · entry 1 Ross Leonard S · CIK 0001458753 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:03 UTC |
Lurker NancyDirector · President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003675 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:03 UTC |
Lurker NancyDirector · President & CEO
|
Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003675 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:04 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003676 · primarydocument.xml · derivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 27, 2017, the reporting person was granted 30,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:04 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 2,940 | $1.65 | $4,851.00 |
DisclosureSEC source: 0001562180-19-003676 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,497 F2 · shares: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 21:04 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003676 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 16:50 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003663 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-21 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:51 UTC |
Peterson KristineDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003664 · primarydocument.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-21 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 16:51 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003666 · primarydocument.xml · derivative · entry 1 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-21 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:50 UTC |
Lurker NancyDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 930,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003662 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,000 Underlying: Common Stock · 930,000 shares Expires 2029-02-21 F2 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 21, 2019 Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:50 UTC |
Lurker NancyDirector · President & CEO
|
GrantRestricted Stock Units · Derivative | 411,523 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003662 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,523 Underlying: Common Stock · 411,523 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 21, 2020. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 21, 2020. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 16:49 UTC |
Price DavidCFO
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003661 · primarydocument.xml · derivative · entry 1 Price David · CIK 0001449336 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-02-21 F1 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 21, 2019 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.